Related Experiment Video

Updated: Jul 6, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Management of advanced prostate cancer: can we improve on androgen deprivation therapy?

John Anderson1, Per-Anders Abrahamsson, David Crawford

  • 1Department of Urology, The Royal Hallamshire Hospital, Sheffield, UK. johnanderson@clara.co.uk

BJU International
|March 14, 2008
PubMed

Insights

Gonadotrophin-releasing hormone (GnRH) agonists are standard for advanced prostate cancer, but newer GnRH blockers like degarelix may offer superior testosterone suppression for better outcomes.

Area of Science:

  • Oncology
  • Endocrinology

Background:

  • Gonadotrophin-releasing hormone (GnRH) agonists are the primary treatment for advanced prostate cancer, suppressing testosterone to slow tumor growth.
  • GnRH agonists have replaced surgical castration (orchidectomy) due to patient preference, but may be less effective in testosterone suppression.

Purpose of the Study:

  • To evaluate the effectiveness of GnRH agonists in androgen-deprivation therapy for advanced prostate cancer.
  • To explore the need for newer agents that achieve rapid, profound, and sustained testosterone suppression comparable to orchidectomy.

Main Methods:

  • Review of current management strategies for advanced prostate cancer using GnRH agonists.
  • Analysis of evidence comparing testosterone suppression levels and speed between GnRH agonists and orchidectomy.
  • Consideration of preliminary data for GnRH blockers, such as degarelix.

Main Results:

  • GnRH agonists effectively slow tumor growth by reducing testosterone levels.
  • Evidence suggests GnRH agonists may not achieve the same depth or speed of testosterone suppression as orchidectomy.
  • Preliminary data indicate GnRH blockers might address the limitations of GnRH agonists.

Conclusions:

  • There is a need for androgen-deprivation therapies that provide more effective testosterone suppression than current GnRH agonists.
  • GnRH blockers like degarelix show promise in overcoming the shortcomings of GnRH agonists.
  • Further clinical investigation of GnRH blockers is warranted for advanced prostate cancer management.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...